Biotech Voices

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Our contributors are not paid for their opinions.

Have any questions or feedback, or think you have a voice that should be heard? Reach out to Amber Tong.

Biotech Voices

Biotech Voices channel feed

#trek­for­to­mor­row #3: How to sur­vive the rig­ors of the Pa­cif­ic Crest Trail and a ca­reer in can­cer re­search

3 weeks ago
R&D

#trek­for­to­mor­row: Ear­ly lessons from the trail

Last month
People
R&D

A ca­reer in can­cer re­search turns out to be the per­fect prep for a gru­el­ing per­son­al ad­ven­ture

2 months ago

Com­pas­sion­ate Use/Ex­pand­ed Ac­cess pro­grams: Three steps to im­prove their im­ple­men­ta­tion for the ben­e­fit of all

11 months ago

Guest col­umn: What hap­pened with Es­pe­ri­on — and what de­fines suc­cess or fail­ure?

Last year

6 key clin­i­cal tri­al trends that we should em­brace and build on

Last year

8 ways Chi­na could help trans­form the glob­al bio­phar­ma in­dus­try

Last year

Ad­u­canum­ab has its ap­proval — now, let cit­i­zen-sci­en­tists come to­geth­er to see if it works

Last year

RNA: From the mes­sen­ger to the med­i­cine

3 years ago

The right to vote is fun­da­men­tal — a let­ter from biotech­nol­o­gy in­dus­try lead­ers

3 years ago
People

The con­tin­u­ing CRISPR patent saga

3 years ago

In­no­va­tion in the clin­ic is pick­ing up steam. How adap­tive de­signs could pave the road to per­son­al­ized med­i­cine

3 years ago

How we are stay­ing con­nect­ed when we’re apart

3 years ago

The path to NASH: un­der­stand­ing the role of se­vere obe­si­ty in a com­plex, mul­ti-sys­tem dis­ease

3 years ago

In­dus­try lead­ers need to speak out now more than ever

3 years ago

Why mu­cos­al im­mu­ni­ty may be re­quired to end the pan­dem­ic

3 years ago

How will the Biden ad­min­is­tra­tion af­fect fund­ing for life sci­ence re­search?

3 years ago

Re­vis­it­ing the 'cy­tokine stor­m' in ARDS; the painful wait for an­ti-in­flam­ma­to­ry drugs/tar­gets that solve Covid-19 deaths

3 years ago

We’re poised for a new era of med­ical ad­vances. A key step: un­der­stand­ing the mol­e­c­u­lar ma­chines that gov­ern health and dis­ease

3 years ago

Next-gen ther­a­pies are evolv­ing fast. The drug de­vel­op­ment mod­el needs to keep up

3 years ago

Bio­science in­dus­try stake­hold­er col­lab­o­ra­tion key to ad­dress­ing in­equal­i­ty

3 years ago

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

4 years ago
Coronavirus

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

4 years ago
Financing
China

Drug dis­cov­ery in the age of coro­n­avirus

4 years ago
Coronavirus
12 Next page Last page
A service from the Financial Times